糖尿病腎病變與心血管疾病

Diabetic Kidney Disease and Cardiovascular Disease

裘亮德(Liang-Te Chiu) ； 徐邦治(Bang-Gee Hsu)

《腎臟與透析》 32卷2期 (2020/06) Pp. 75-78

https://doi.org/10.6340/KD.202006_32(2).0005

摘要

糖尿病腎病變（diabetic kidney disease, DKD）的典型表現，除了腎功能逐年下降，更伴隨高血壓及蛋白尿的發生，最後進展為末期腎臟疾病（end-stage renal disease, ESRD）或是死亡。除了心血管疾病傳統的危險因子（如高血壓、高血脂）常與糖尿病伴隨出現之外，糖尿病人有其特有的致病機轉。治療上除了應該按照糖尿病的治療指引積極控制血糖、血壓、血脂以外，目前有一些新機轉的藥物被證明是可以降低糖尿病人心血管事件的風險，包括第2型鈉－葡萄糖共同轉運蛋白（sodium glucose co-transporter 2, SGLT2）抑制劑以及類升糖素胜肽-1（glucagon-like peptide-1, GLP1）受體促效劑。

關鍵字

糖尿病腎病變 ； 心血管疾病 ； SGLT2抑制劑 ； GLP1受體促效劑

並列摘要

The typical manifestation of diabetic kidney disease, in addition to the decline in renal function, is accompanied by the occurrence of hypertension and proteinuria, and finally progresses to end-stage renal disease or death. In addition to the traditional risk factors of cardiovascular disease (such as hypertension, hyperlipidemia) often accompanied by diabetes, people with diabetes have their unique pathogenesis. In addition to aggressive glucose, blood pressure, and lipids control following the guidelines for the treatment of diabetes, there are currently some new drugs that have been proven to reduce the risk of cardiovascular events in people with diabetes, including sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

並列關鍵字

diabetic kidney disease ； cardiovascular disease ； sodium glucose co-transporter 2 (SGLT2) inhibitors ； glucagon-like peptide-1 (GLP1) receptor agonists